PillOTC · Solution · Oral
Guaifenesin And Codeine Phosphate
Codeine Phosphate + Guaifenesin
4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
4 active makers
4 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.049
Latest avg · Jul 22, 2026
+7%
Since Dec 17, 2025
4
Active US suppliers
80%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
19K
Rx · 2026 Q1
3.2M
Units dispensed
-56%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it4 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| PAI Holdings, LLC dba PAI Pharma | unknown | 7 | SUPPLYING |
| A-S Medication Solutions | unknown | 1 | SUPPLYING |
| Cardinal Health 107, LLC | unknown | 1 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jan 7, 2025RECALLRecall (Class III): Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutica…
Superpotent; sodium benzoate preservative — Recalling firm: PAI Holdings, LLC. dba Pharmaceutical Associates Inc — OH